The Role of the Microbiome and Green Tea Catechins in Prostate Cancer: Contemporary Issues in Research | Chapter 7 | Research Developments in Medicine and Medical Science Vol. 8

 Clinical research focus men with local prostate cancers is a challenging endeavor. The guidelines and flags for management - active following versus definitive medicine although well established in current years, patients touch grapple with the decision to persist active surveillance. Accumulating evidence supports green beverage catechins (GTCs) in chemoprevention for prostate cancer (PCa), a leading cause of malignancy morbidity and mortality between men. GTCs include (-)-epigallocatechin-3-gallate, that has been shown to adjust molecular pathways involved in prostate carcinogenesis. Previous research on GTCs submitted that they are bioavailable, safe, and effective at modulating dispassionate and biological markers guide prostate cancer. GTCs may be exceptionally beneficial to those with inferior PCas, which are typically trained with careful listening through active surveillance (AS).  The gut microbiome enzymatically revolutionizes GTC structure when administered verbally, altering its bioavailability, bioactivity, and toxicity. In addition to xenobiotic absorption, the gut microbiome has multiple other corporeal effects potentially complicated in PCa progression, including organizing inflammation, hormones, and other popular/unknown pathways. Therefore, the contemporary approach from now on clinical trials search out  consider not only the independent role of chemopreventive powers such as GTCs, but in addition, contain the synergestic  role of the gut microbiome in the context of PCa chemoprevention, as they can relate to individual responses to GTCs, that, in turn, can enhance dispassionate decision-making.

Author(s) Details:

Nagi B. Kumar,
Cancer Epidemiology Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA and Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Stephanie Hogue,
Cancer Epidemiology Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Julio Pow-Sang,
Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Michael Poch,
Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Brandon J. Manley,
Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Roger Li,
Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Jasreman Dhillon,
Anatomic Pathology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Alice Yu,
Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Doratha A. Byrd,
Cancer Epidemiology Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA and  Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Please see the link here: https://stm.bookpi.org/RDMMS-V8/article/view/10206